Supernus Pharmaceuticals, Inc. Revenue 2010–2025
Supernus Pharmaceuticals, Inc. reported $718.95M of revenue for fiscal 2025. That was 8.6% higher than fiscal 2024. Compared with fiscal 2020, the change was +38.2%.
| Fiscal year | Revenue | Change (YoY) |
|---|---|---|
| FY 2025 | $718.95M | +8.6% |
| FY 2024 | $661.82M | +8.9% |
| FY 2023 | $607.52M | -8.9% |
| FY 2022 | $667.24M | +15.1% |
| FY 2021 | $579.77M | +11.4% |
| FY 2020 | $520.40M | +32.5% |
| FY 2019 | $392.75M | -3.9% |
| FY 2018 | $408.90M | +35.3% |
| FY 2017 | $302.24M | +40.6% |
| FY 2016 | $215.00M | +45.8% |
| FY 2015 | $147.47M | +59.1% |
| FY 2014 | $92.68M | +671.1% |
| FY 2013 | $12.02M | +712.1% |
| FY 2012 | $1.48M | +84.3% |
| FY 2011 | $803,000 | +657.5% |
| FY 2010 | $106,000 | — |
Source: Supernus Pharmaceuticals, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open SUPN 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Supernus Pharmaceuticals, Inc. reported $718.95M of revenue for fiscal 2025. That was 8.6% higher than fiscal 2024. Compared with fiscal 2020, the change was +38.2%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Supernus Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeSupernus Pharmaceuticals, Inc. — frequently asked questions
What is Supernus Pharmaceuticals, Inc.'s revenue?
Supernus Pharmaceuticals, Inc. (SUPN) reported revenue of $718.95M for fiscal year 2025, per its SEC filings.
How has Supernus Pharmaceuticals, Inc.'s revenue changed over time?
Between fiscal 2010 and 2025, SUPN's revenue grew at roughly 80.1% per year (compound annual rate), from $106,000 to $718.95M.
Where does this data come from?
Figures are computed from Supernus Pharmaceuticals, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.